



# Combat Drugs Limited

Regd. Off: 9-109/9, Plot No.112, Road No.14, Gayatri Nagar, Bouduppal, R.R.District -500039, TS  
Ph: +91-40-66200100 / 65523363 Url: www.combatdrugs.in Email: info@combatdrugs.in  
CIN No.:L24230TG1986PLC006781 TIN:36690236431 D.L.No.: TG/15/04/2016-14766 /14767

30/05/2017

To,  
The General Manager  
Department of Corporate Services - CRD  
Bombay Stock Exchange Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai 400 001

Dear Sir,

**Subject: Outcome of Board Meeting – Quarterly Results**

Pursuant to Regulation 29 & 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that at the meeting of the Board of Directors of the company held today ie; 30<sup>th</sup> May, 2017, the Statement of Audited Financial Results for the quarter ended 31<sup>st</sup> March, 2017 was approved and taken on record along with the Limited Review Report for the period issued by the Statutory Auditors of the company.

Please find enclosed the following in respect of the above said:

1. Statement of Audited Financial Results for the Quarter ended 31<sup>st</sup> March, 2017.
2. Limited Review Report of the Auditors on Quarterly Financial Results pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information and records

Thanking You,  
Yours Sincerely,  
For **COMBAT DRUGS LIMITED**

Kiran Kumar K  
**COMPLIANCE OFFICER**



**COMBAT DRUGS LIMITED**  
(CIN: CL23230TG1986PLC006781)

Regd.off: 9-109/9, Plot No.112, Road No.14,  
Gayatri Nagar, Bouduppall R.R. Dist-500039  
, Telangana India

Ph: 040-66200100  
URL: www.combatdrugs.in  
Mail: info@combatdrugs.in

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2017


(Rs. In lakhs)

Particulars	Quarter ended			Year ended	
	31.03.2017	31.12.2016	31.03.2016	31.03.2017	31.03.2016
	Audited	Unaudited	Audited	Audited	Audited
<b>Income</b>					
I Revenue from operations	9.27	15.31	5.46	37.50	22.30
II Other Income	-	-	0.15	-	0.55
<b>III Total Revenue</b>	<b>9.27</b>	<b>15.31</b>	<b>5.61</b>	<b>37.50</b>	<b>22.85</b>
<b>IV Expenses</b>					
a) Cost of materials consumed	6.73	12.00	3.21	26.44	11.31
b) Employee benefits expenses	(0.48)	7.02	7.79	15.70	12.38
c) Other expenses	2.22	1.57	71.64	13.80	118.37
d) Depreciation	-	-	-	-	8.56
<b>Total Expenses</b>	<b>8.47</b>	<b>20.59</b>	<b>82.64</b>	<b>55.94</b>	<b>150.62</b>
<b>V Profit / (Loss) before Tax</b>	<b>0.80</b>	<b>(5.28)</b>	<b>(77.03)</b>	<b>(18.44)</b>	<b>(127.77)</b>
Tax expense					
- Current Tax	-	-	-	-	-
- Deferred Tax	-	-	-	-	-
<b>VI Profit / (Loss) after tax</b>	<b>0.80</b>	<b>(5.28)</b>	<b>(77.03)</b>	<b>(18.44)</b>	<b>(127.77)</b>
<b>VII Paid up equity share capital (Face value Rs.10/-)</b>	<b>800</b>	<b>800</b>	<b>800</b>	<b>800</b>	<b>800</b>
<b>VIII Earning per share(EPS) (of Rs.10/- each) (not annualised)</b>					
a) Basic	0.01	(0.07)	(0.96)	(0.23)	(1.60)
b) Diluted	0.01	(0.07)	(0.96)	(0.23)	(1.60)

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 30.05.2017.
- The figures of the last quarter for the current year and previous year are the balancing figures between the audited figures in respect of full financial year ended 31.03.2017 and 31.03.2016 and the unaudited published year to date figures upto the third quarter ended 31.12.2016 and 31.12.2015 respectively, which were subject to a limited review.
- The Company is operating in only one segment i.e., Pharmaceuticals and hence segment-wise reporting is not applicable.
- Previous year's / period's figures have been regrouped / rearranged / recasted / wherever necessary

Place: Hyderabad  
Date: 30.05.2017



For and on behalf of the Board of Directors  
COMBAT DRUGS LIMITED

MANAGING DIRECTOR

**COMBAT DRUGS LIMITED**  
**STATEMENT OF ASSETS AND LIABILITIES**

(Rs. In lakhs)

PARTICULARS	As at	As at
	31.03.2017	31.03.2016
	AUDITED	AUDITED
<b>I EQUITY AND LIABILITIES</b>		
<b>SHAREHOLDERS'S FUNDS:</b>		
a)Share capital	800.00	800.00
b)Reserves and Surplus	(606.22)	(587.78)
<b>Non-current Liabilities</b>		
Long term borrowings	4.79	-
<b>Current Liabilities</b>		
a) Trade payables		
Total outstanding dues of micro enterprises and small enterprises	-	-
Total outstanding dues of creditors other than micro enterprises and small enterprises	46.16	39.26
b) Other current liabilities	12.59	9.24
<b>TOTAL</b>	<b>257.32</b>	<b>260.72</b>
<b>II ASSETS</b>		
<b>Non-Current Assets</b>		
a)Property,Plant and Equipment	-	-
b)Long term loans and advances	221.95	221.65
<b>Current Assets</b>		
a)Inventories	7.02	21.02
b)Trade Receivables	13.52	7.18
c)Casn and bank balances	3.46	0.28
d)Short term loans and advances	11.37	10.59
<b>TOTAL</b>	<b>257.32</b>	<b>260.72</b>

Place: Hyderabad  
Date: 30.05.2017



On behalf of the Board of Directors  
COMBAT DRUGS LIMITED  
*[Signature]*  
MANAGING DIRECTOR


**M. ANANDAM & CO.,**  
CHARTERED ACCOUNTANTS

**Auditor's Report on Quarterly Financial Results and Year to Date Results of Combat Drugs Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To

Board of Directors of Combat Drugs Limited

1. We have audited the quarterly financial results of Combat Drugs Limited (the Company) for the quarter ended 31<sup>st</sup> March, 2017 and the year to date results for the period 1<sup>st</sup> April, 2016 to 31<sup>st</sup> March, 2017 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial results, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS - 25), "Interim Financial Reporting", specified under Section 133 of the Companies Act, 2013, read with Rule 7 of Companies (Accounts) Rules 2014 and other accounting principles generally accepted in India.
2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.
3. In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:
  - (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016; and
  - (ii) give a true and fair view of the net profit and other financial information for the quarter ended 31<sup>st</sup> March, 2017 as well as the year to date results for the period from 1<sup>st</sup> April, 2016 to 31<sup>st</sup> March, 2017.



M.Anandam & Co.,  
Chartered Accountants

4. The statement includes the results for the Quarter ended 31<sup>st</sup> March, 2017, being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

Place: Secunderabad  
Date: 30.05.2017



For M.Anandam & Co.,  
Chartered Accountants  
(Firm Regn.No.000125S)

  
A.V.Sadasiva

Partner

Membership No. 018404